Is SS-31 Legal? (Regulatory Status Explained)

Is SS-31 Legal? (Regulatory Status Explained)

Research from clinical trials funded by the National Institutes of Health has documented SS-31's potential to protect mitochondria from oxidative damage in cardiac ischemia models. Yet patients searching for this peptide discover an opaque supply chain with no FDA-approved prescription product available. The disconnect between published efficacy data and regulatory access creates confusion that goes beyond inconvenience: missteps in sourcing or labeling SS-31 can trigger legal consequences for both suppliers and end users.

We've guided research institutions and individual clients through this exact regulatory landscape. The line between compliant research use and illegal therapeutic use is razor-thin, and most guides gloss over the distinctions that matter most.

Is SS-31 legal to buy and use?

SS-31 (elamipretide) is legal to purchase and possess in the United States exclusively for research purposes. It is not FDA-approved for clinical use, meaning any sale or distribution marketed for human consumption, disease treatment, or therapeutic application violates federal law. Research-grade SS-31 from licensed suppliers like Real Peptides is legal under 21 CFR 312.2(b)(1) as an investigational compound, provided labeling and marketing materials explicitly state "for research use only. Not for human consumption."

The Regulatory Classification of SS-31 in 2026

SS-31 (also known as elamipretide, Bendavia, and MTP-131) is classified as an investigational new drug (IND) that has completed Phase II clinical trials for primary mitochondrial myopathy and Barth syndrome but has never received FDA approval as a therapeutic agent. This means the compound exists in a legally defined space: permitted for laboratory research, prohibited for off-label therapeutic use. The Federal Food, Drug, and Cosmetic Act (FFDCA) Section 505 mandates that any substance intended to diagnose, cure, mitigate, treat, or prevent disease in humans must undergo New Drug Application (NDA) approval. SS-31 has not. Suppliers who market SS-31 with therapeutic claims, dosage protocols, or outcome promises violate 21 U.S.C. § 331(d), which prohibits introduction of unapproved new drugs into interstate commerce.

The peptide's mechanism of action. Selective binding to cardiolipin on the inner mitochondrial membrane to reduce reactive oxygen species (ROS) production. Has been characterized in peer-reviewed publications including studies published in Circulation Research and the Journal of Cardiovascular Pharmacology, yet this scientific validation does not confer legal therapeutic status. Research institutions purchasing SS-31 for in vitro studies, animal models, or investigational protocols operate under Institutional Review Board (IRB) oversight when human subjects are involved, or Institutional Animal Care and Use Committee (IACUC) protocols for preclinical work. Individual consumers cannot replicate this compliance framework at home.

Real Peptides supplies SS-31 Elamipretide with explicit research-only labeling, batch-specific certificates of analysis, and purity verification via high-performance liquid chromatography (HPLC). The documentation that differentiates compliant research supply from illegal therapeutic distribution. The compound itself is not a controlled substance under the Controlled Substances Act (CSA) schedules I-V, meaning possession alone does not trigger DEA enforcement. But misuse, mislabeling, or marketing for human therapy does.

How SS-31 Legal Status Differs from FDA-Approved Peptides

The distinction between SS-31 and FDA-approved peptides like semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro) is not a matter of molecular safety. It's a matter of completed regulatory pathways. FDA approval requires demonstration of safety and efficacy across Phase I, II, and III randomized controlled trials, submission of manufacturing protocols under Good Manufacturing Practice (GMP) standards, and post-market surveillance systems. SS-31 completed a Phase II trial (NCT02367014) for Barth syndrome showing statistically significant improvements in 6-minute walk distance and left ventricular function. But the sponsor (Stealth BioTherapeutics) did not proceed to Phase III at scale, leaving the compound without the data package required for NDA submission.

FDA-approved peptides carry National Drug Code (NDC) numbers, prescribing information approved by the FDA, and legal pathways for off-label prescribing under the practice of medicine exception (21 U.S.C. § 396). SS-31 has none of these. A physician cannot legally prescribe SS-31 for therapeutic use because it is not an approved drug product. Doing so constitutes introduction of an unapproved drug, actionable under FDA enforcement discretion. Compounding pharmacies operating under 503A (traditional compounding) or 503B (outsourcing facilities) authority cannot compound SS-31 for individual patient prescriptions because compounding law requires the bulk active pharmaceutical ingredient (API) to be an FDA-approved substance or appear on the FDA's bulks list under 21 CFR 216.23. SS-31 appears on neither.

Patients sometimes assume "research peptides" occupy the same legal space as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). They do not. Supplements must be intended for ingestion to supplement the diet and cannot make drug claims. SS-31 is a synthetic tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) with a defined pharmacological mechanism targeting mitochondrial membranes. It is a drug candidate, not a supplement. Suppliers who market SS-31 as a supplement, or with language suggesting it "supports mitochondrial health" in humans, violate both FFDCA drug approval requirements and Federal Trade Commission (FTC) truth-in-advertising standards.

The practical consequence: FDA-approved peptides like Tirzepatide can be legally prescribed, dispensed, and used therapeutically. SS-31 cannot. Not because it is dangerous, but because the regulatory process was never completed. Real Peptides addresses this by restricting sales to research applications and providing the technical documentation (purity certificates, amino acid sequencing verification, sterility testing) that laboratories require to justify procurement under institutional research budgets.

Legal Compliance Requirements for SS-31 Suppliers and Buyers

Compliance begins with labeling. Under 21 CFR 201.128, any drug product label must include adequate directions for use. But SS-31, as an unapproved investigational compound, cannot include such directions without triggering the requirement for FDA approval. The regulatory workaround: explicit "not for human consumption" and "for research use only" disclaimers on all product labeling, marketing materials, and transactional documentation. Suppliers who omit these disclaimers, or who provide dosage protocols, injection guides, or outcome testimonials, convert a legal research chemical sale into an illegal drug distribution.

Purchasers. Whether academic institutions, contract research organizations (CROs), or private laboratories. Must document the research purpose of procurement. Institutional buyers operate under Material Transfer Agreements (MTAs) or purchase orders that reference specific research protocols, grant numbers, or IRB/IACUC approvals. Individual buyers purchasing SS-31 for personal use face a higher compliance burden: without institutional affiliation, the research justification becomes harder to substantiate. While possession of SS-31 is not illegal, possession with intent to use for therapeutic self-administration creates liability if the peptide is later linked to an adverse event. The FDA's authority under 21 U.S.C. § 331(k) to seize misbranded drugs extends to products held for illegal use even if the holder is not the original seller.

Payment processing provides another compliance signal. Credit card networks (Visa, Mastercard) and payment processors (Stripe, Square) enforce Acceptable Use Policies (AUPs) that prohibit transactions for unapproved pharmaceuticals marketed for human consumption. Suppliers who describe SS-31 with therapeutic language may find merchant accounts suspended. Not due to government action, but due to private platform risk assessment. Real Peptides maintains compliance by using transaction descriptors that reference research chemicals and laboratory supplies, not health outcomes.

Importation adds another layer. U.S. Customs and Border Protection (CBP) and the FDA's Office of Regulatory Affairs (ORA) inspect international shipments of pharmaceutical compounds under Import Alert 66-41, which targets unapproved new drugs. SS-31 synthesized overseas and shipped to individual consumers can be detained at the port of entry if packaging suggests therapeutic use. Research institutions importing SS-31 under institutional research protocols file prior notice with the FDA and provide documentation of the research application. Individual consumers lack this pathway. Domestic suppliers like Real Peptides eliminate importation risk by sourcing or synthesizing peptides within the United States under contract with FDA-registered facilities, then distributing domestically under research-only terms.

Is SS-31 Legal: Status Comparison

Understanding where SS-31 fits within the broader regulatory landscape requires comparing it to similar compounds across different legal classifications. The following table maps SS-31's status against FDA-approved peptides, other investigational compounds, and controlled substances.

Key Takeaways

• SS-31 (elamipretide) is legal to purchase and possess in the United States exclusively for research purposes. It is not FDA-approved for clinical or therapeutic use in 2026.
• Suppliers must label SS-31 as "for research use only. Not for human consumption" to comply with 21 CFR 201.128 and avoid FDA enforcement under 21 U.S.C. § 331(d) for distribution of unapproved new drugs.
• SS-31 completed Phase II trials (NCT02367014) for Barth syndrome with statistically significant efficacy signals, but the sponsor did not advance to Phase III. Leaving the compound without the data required for New Drug Application (NDA) approval.
• Compounding pharmacies operating under 503A or 503B authority cannot legally compound SS-31 for individual patient prescriptions because it is not an FDA-approved bulk API and does not appear on the FDA's approved bulks list under 21 CFR 216.23.
• Real Peptides supplies SS-31 Elamipretide with batch-specific certificates of analysis, HPLC purity verification, and research-only labeling to ensure compliance with federal investigational compound regulations.
• Possession of SS-31 is not federally illegal, but using it for self-administration or distributing it with therapeutic claims violates the Federal Food, Drug, and Cosmetic Act and exposes both suppliers and users to FDA enforcement action.

What If: SS-31 Legal Scenarios

What If I Purchase SS-31 for Personal Health Use — Can I Be Prosecuted?

Purchasing SS-31 for personal health use is not a criminal offense under federal law, but using it therapeutically without medical supervision creates civil liability and enforcement risk. The FDA does not typically prosecute individual consumers for personal possession of unapproved drugs. Enforcement targets suppliers and distributors under 21 U.S.C. § 331(a) and (d). However, if you experience an adverse event and seek medical treatment, healthcare providers are required to report serious adverse events to the FDA's MedWatch system, which can trigger an investigation into the source of the unapproved drug. If the supplier marketed SS-31 with therapeutic claims or dosage protocols, the FDA may issue a warning letter, injunction, or seizure order. And your purchase history becomes part of the enforcement record.

What If My Research Institution Wants to Use SS-31 in a Clinical Study?

Clinical use of SS-31 in human subjects requires an Investigational New Drug (IND) application submitted to the FDA under 21 CFR 312. Your institution's principal investigator must file the IND with a detailed protocol, safety data from prior studies, manufacturing and chemistry information (CMC), and IRB approval before enrolling the first participant. The IND pathway is the only legal mechanism for administering SS-31 to humans outside of an approved therapeutic indication. Research-grade SS-31 from suppliers like Real Peptides can serve as the source material, provided the supplier provides the documentation required for IND submission. Including certificates of analysis, sterility testing, endotoxin levels, and amino acid sequencing. Administering SS-31 to human subjects without an active IND is illegal and exposes the institution to FDA enforcement, loss of federal research funding, and civil liability.

What If I'm a Physician and a Patient Asks Me to Prescribe SS-31?

You cannot legally prescribe SS-31 because it is not an FDA-approved drug. Prescribing an unapproved new drug violates the Federal Food, Drug, and Cosmetic Act regardless of your clinical judgment or the patient's informed consent. The "practice of medicine" exception under 21 U.S.C. § 396 permits off-label prescribing of approved drugs but does not extend to unapproved investigational compounds. If you write a prescription for SS-31, compounding pharmacies operating under 503A or 503B cannot fill it because SS-31 is not an approved bulk API. If you direct the patient to a research supplier and suggest dosage or administration protocols, you may be deemed to have introduced an unapproved drug into interstate commerce under a theory of aiding and abetting distribution, exposing yourself to professional discipline and FDA enforcement. The only legal pathway is to enroll the patient in a clinical trial operating under an active IND.

The Blunt Truth About SS-31 Legal Status

Here's the honest answer: SS-31 is not illegal to buy, but it is illegal to use therapeutically, and most suppliers obscure that distinction because their revenue depends on the ambiguity. The FDA has not banned SS-31, scheduled it as a controlled substance, or prohibited research use. But the agency has also not approved it, which means every sale for human health purposes violates federal law whether or not the FDA chooses to enforce. The enforcement calculus favors suppliers over individual buyers, meaning the person who sold you SS-31 with a dosage protocol faces far higher legal risk than you do for using it. But both actions are non-compliant. The published clinical data on SS-31's mitochondrial protection mechanisms is legitimate, the safety profile from Phase II trials is encouraging, and the lack of FDA approval is a function of commercial and regulatory strategy, not inherent danger. But none of that changes the legal reality that therapeutic use in 2026 remains prohibited under the FFDCA.

SS-31 sits in the same regulatory space as dozens of other promising investigational peptides. Compounds with strong preclinical and early clinical data that never completed the approval process due to funding constraints, market size concerns, or sponsor strategic decisions. The real risk isn't prosecution for personal use; it's the absence of oversight. When you use an unapproved drug, you assume all pharmacokinetic variability, all risk of contamination or mislabeling, and all liability for adverse events. And you do so without the legal protections that FDA approval guarantees. Real Peptides mitigates some of that risk by providing third-party purity testing and proper labeling, but no research supplier can convert an investigational compound into an approved therapeutic agent.

For researchers working within institutional frameworks, SS-31 is a valuable tool supported by decades of mitochondrial biology research and a clear mechanistic rationale for studying ischemia-reperfusion injury, age-related mitochondrial dysfunction, and primary mitochondrial diseases. Our full peptide collection includes other mitochondrial-targeted compounds like MOTS-c and Epithalon, each with distinct mechanisms and regulatory considerations. And all supplied with the documentation, purity standards, and compliance labeling that legitimate research applications demand.

If your application is genuine laboratory research, SS-31 is legal and accessible. If your intent is therapeutic self-administration, the compound's legal status hasn't changed since the last trial data was published. It remains an investigational agent without approval, and using it therapeutically remains non-compliant regardless of how compelling the preclinical data appears.